VAERS 2101014
MERCK & CO. INC. · HEP A (VAQTA) · Charge U002749
- Staat
- OH
- Alter
- -
- Geschlecht
- U
- Eingang
- 10.02.2022
- Impfdatum
- 29.12.2021
- Beginn
- 29.12.2021
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Symptomtext
No additional AE or PQC reported; VAQTA and RECOMBIVAX HB were administered after a temperature excursion; This spontaneous report as received from an office manager refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions, allergies and concomitant therapies was provided. On 29-DEC-2021, after a temperature excursion, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) prefilled syringe, 0.5 ml, lot # U002749, expiry date 04-MAY-2022 (route and site of administration were not reported) and with and hepatitis b vaccine (recombinant) (RECOMBIVAX HB), 0.5 ml, lot # T007984, expiry date 01-NOV-2022 (route and site of administration were not reported), both for prophylaxis (product storage error). The vaccines experienced a temperature excursion, however a specific temperature and timeframe were unknown by the reporter. It was unknown if a previous temperature excursion occurred. No additional adverse event was reported (no adverse event).
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -